Patent: 5,270,181
✉ Email this page to a colleague
Summary for Patent: 5,270,181
| Title: | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
| Abstract: | This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion. |
| Inventor(s): | McCoy; John (Reading, MA), LaVallie; Edward R. (Tewksbury, MA) |
| Assignee: | Genetics Institute, Inc. (Cambridge, MA) |
| Application Number: | 07/745,382 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,270,181
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Wyeth Pharmaceuticals Inc. | NEUMEGA | oprelvekin | For Injection | 103694 | November 25, 1997 | ⤷ Sign Up | 2011-02-06 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
